Chong Kun Dang Q3 Operating Profit Up 15.4% YoY... "Wegovy Effect"

Revenue of 430.7 Billion Won, Operating Profit of 23.7 Billion Won

Chong Kun Dang's operating profit in the third quarter of this year increased, buoyed by existing products and the introduction of new products, including Wegovy.

Chong Kun Dang headquarters on Chungjeong-ro in Seodaemun-gu, Seoul. The Asia Business Daily DB

On October 30, Chong Kun Dang disclosed that, on a separate financial statements basis, it recorded revenue of 430.7 billion won and operating profit of 23.7 billion won in the third quarter. Revenue rose 0.8% and operating profit increased 15.4% year over year. Net profit for the same period fell 6.5% to 18.8 billion won.

Cumulative revenue for the first three quarters of this year was 1.3538 trillion won, up 7.8% year over year. Cumulative operating profit rose 10.2% to 61.2 billion won. By contrast, cumulative net profit fell 3.6% year over year.

The improvement in results was driven by newly introduced products. A key product is Wegovy, an obesity treatment that Chong Kun Dang has been co-selling with Novo Nordisk since October 2025. A Chong Kun Dang representative said, "In addition to our existing products maintaining solid performance, the introduction of new products also contributed. As overall revenue increased, operating profit also performed well."

This content was produced with the assistance of AI translation services.